Indosol Drugs Profile
Key Indicators
- Authorised Capital ₹ 10.00 Cr
- Paid Up Capital ₹ 7.50 Cr
- Company Age 36 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 18.96 Cr
- Revenue Growth -28.30%
- Profit Growth -11.66%
- Ebitda -7.34%
- Net Worth -2.11%
- Total Assets -22.60%
About Indosol Drugs
Indosol Drugs Limited (IDL) is a Public Limited Indian Non-Government Company incorporated in India on 07 July 1988 and has a history of 36 years and six months. Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 10.00 Cr and a paid-up capital of Rs 7.50 Cr.
The company has closed loans amounting to ₹18.96 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Company Details
-
Location
Mumbai, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24230MH1988PLC047992
-
Company No.
047992
-
Company Classification
Public Limited Indian Non-Government Company
-
Incorporation Date
07 Jul 1988
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Indosol Drugs?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Niranjan Shah
|
Director | 06-Sep-2004 | Current |
|
Chirag Shah
|
Director | 23-Feb-1994 | Current |
|
Virendra Shah
|
Director | 07-Jul-1988 | Current |
Financial Performance of Indosol Drugs.
Indosol Drugs Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 28.3% decrease. The company also saw a substantial fall in profitability, with a 11.66% decrease in profit. The company's net worth dipped by a decrease of 2.11%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Indosol Drugs?
In 2022, Indosol Drugs had a promoter holding of 45.33% and a public holding of 54.67%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0
₹18.96 Cr
Charges Breakdown by Lending Institutions
- Central Bank Of India : 18.96 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 30 Apr 2002 | Central Bank Of India | ₹18.96 Cr | Satisfied |
How Many Employees Work at Indosol Drugs?
Indosol Drugs has a workforce of 4 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Indosol Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Indosol Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.